{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.4","upperLimit":"94.5","value":"66.7"},{"groupId":"OG001","lowerLimit":"67.6","upperLimit":"93.5","value":"85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"OS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Each participant in the dose-finding cohort must have completed at least cycle 1 (or 21 days) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). Starting dose of ibrutinib is 560 mg PO.","id":"OG000","title":"Dose-finding Cohort"},{"description":"Each participant in the dose expansion cohort may receive treatment for a maximum of 6 cycles (21-day cycle length) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). MTD of ibrutinib is 560 mg PO.","id":"OG001","title":"Dose Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"Participants received study treatment (ibrutinib plus R-da-EPOCH)","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}